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ABSTRACT
Study design: Experimental study. Objective: The aim of this study was the characterization and
evaluation of the anti-inflammatory activity of an implantable polymer system containing sodium
diclofenacin carrageenan-induced acute inflammation in a rat kneemodel. Methodology: An implantable
device made of Eudragit RS 100 and PCL-T containing 3.0 mg of sodium diclofenac was produced by
casting. The device showed similar mechanical properties to elastomeric polymer products. The mecha-
nism of sodium diclofenac release from the Eudragit and PLC-T matrix showed two stages: first, a rapid
release and then a slow release with a zero-order kinetic behavior. The devices were implanted in the
articular joint of the posterior area of the arthritis-induced knees of rats. Results: Within 6 hours and
on day 7 after arthritis induction, the knee edema was evaluated, and the inflammatory mediators,
myeloperoxidase (MPO) and nitric oxide were analyzed. The results were compared with oral adminis-
tration of 30 mg/kg of sodium diclofenac. Conclusion: The proposed implantable device was able to
produce similar anti-inflammatory results in carrageenan-induced arthritis compared with oral treat-
ment, but at lower doses.
Keywords: Osteoarthritis. Drug Delivery Systems, Implantable. PCL-T. Inflammation. Diclofenac / Sodium.
Rats.
RESUMO
Modelo do estudo: experimental. Objetivo do estudo: produzir, descrever e avaliar a atividade anti-
inflamatória de um sistema polimérico implantável contendo diclofenaco de sódio na inflamação aguda
induzida por carragenina em um modelo de artrite emjoelho de ratos. Metodologia: Um dispositivo
implantável de Eudragit RS 100 e PCL-T (EUDPCL-T) contendo 3.0 mg de diclofenaco de sódio foi produ-
zido. Os dispositivos foram implantados na região peri-articular posterior dos joelhos de ratos induzidos
a artrite. Resultados: Após 6 horas e no dia 7 após a indução de artrite, o edema do joelho foi avaliado,
e os mediadores inflamatórios, mieloperoxidase (MPO) e óxido nítrico foram analisados. Os resultados
foram comparados com a administração oral de 30 mg / kg de diclofenaco de sódio. Conclusões: O
dispositivo implantável foi capaz de produzir os mesmos resultados anti-inflamatórios na artrite induzida
por carragenina quando comparadoscom o tratamento por via oral, entretanto com doses mais baixas.
Palavras-chave: Osteoartrite. Sistemas Implantáveis de Liberação de Medicamentos. PCL-T.
Inflamação. Diclofenaco/ Sódio . Ratos.
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Introduction
In recent decades, the search for new tech-
nologies to provide controlled release of medica-
tions had a big boost. Research seeking materials
that can lead to constant drug release over an ex-
tended period was achieved with the use of various
chemical composition systems that can provide con-
trolled drug delivery.1,2
Controlled drug-delivery systems have the
advantage of improved drug efficacy, reducing tox-
icity and increasing comfort and adherence to treat-
ment. Studies have demonstrated a superior effi-
cacy compared with conventional methods of ad-
ministering drugs, but few products are currently
available for clinical use. Many of these systems are
in early stages of development, and a number of
questions are yet to be answered.1-7
The non-steroidal anti-inflammatory drugs
(NSAIDs) are among the most commonly consumed
medications in the world. They are used to decrease
pain and inflammation caused by various diseases,
such as in the treatment of arthritis.8However, the
continuous use of NSAIDs is directly associated with
gastrointestinal, cardiovascular and renal compli-
cations. NSAID-related morbidity and mortality are
well known in the scientific community. For that rea-
son, there is a recommendation to use these drugs
in the lowest effective dose and for the shortest
possible time.8-11
This study was aimed at producing and as-
sessing anti-inflammatory activity of an implantable
system for sodium diclofenacdelivery in an articular
joint to promote drug activity at lower doses than
those used orally, thus reducing unwanted side ef-
fects.
Materials and methods
Production of implantable device
To produce the implantable device, 1350 mg
of Eudragit-L (Evonik Industries, Essen, Germany),
600 mg of PCL-T (Aldrich Chemical Co. Inc., St. Louis,
USA) and 860 mg of sodium diclofenac (SA Galena,
São Paulo, Brazil) were previously dissolved in 35
ml of ethanol. The solution was poured into a Teflon
plate measuring 26.34 cm2, and maintained in fume
hood at 25 ± 5°C until completely dry. The pro-
duced films containing 32.6 mg/cm2sodium
diclofenac were kept in a desiccator for further char-
acterization. Devices measuring 1 mm wide and 11
mm long were molded for in vivo testing.
Mechanical analysis
A dynamic-mechanical analysis equipment
Model DMA Q800 from TA Instruments was used to
examine the device. The tests were conducted at a
constant temperature of 37°C and 1N/min loading
rate up to a maximum force of 18 N. Assessment of
the responses encompassed the elastic modulus
strain in the range between 0.2% and 0.4%, maxi-
mum stress (MPa) and breaking strain (%) (N > 3).
Release studies
The release studies were performed using
dissolution tester Model Etica, with six baskets and
one cell release. The cell was immersed in 350 ml
of phosphate buffer solution (pH = 7.4) under con-
tinuous stirring at 120 rpm, at 37°C ± 1.0°C. Solu-
tion samples were taken over an 11-day period, and
the concentration of sodium diclofenac released was
determined by UV spectroscopy (Hitachi 2010, Ja-
pan) in lmax 272 nm, and the tests were performed
in triplicate. After each sample collection, an equal
volume of phosphate buffer was added to the dis-
solution medium to maintain constant volume and
sink conditions. The concentration of sodium
diclofenac released from the films was calculated
using the equation of a straight line derived from
the calibration curve of diclofenac obtained from the
analytical method validation. The validated method
showed r = 0.99838, a linear coefficient of 0.0046,
and a slope of 32.9342. The coefficient of variation
between tests was 2.5% (precision) and accuracy
of the presence of formulation components was
98.7%.
Assessment of the anti-inflammatory activity
The in vivo anti-inflammatory activity of the
devices were compared with the same drug admin-
istered orally in carrageenan-induced arthritis rats
models. Fifty-six male Wistar rats (Rattus norvegicus
albinus) 60 days of age, obtained from UNIVALI vi-
varium, weighing 150-200 g, maintained under con-
trolled conditions of luminosity (12-hour light-dark
cycle), temperature (22 ± 2%C), receiving water
and balanced chow ad libitum,were used for the
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experiments. The research project was approved
by the UNISUL Ethics Committee on Animal Experi-
mentation (number 12.013.4.01 IV). The rats were
randomly divided into four groups named DICL (so-
dium diclofenac), EUDPCL-T, CRGN (carrageenan)
and Control, each group containing 14 animals. On
the first day, the rats were anesthetized, weighed
and had the thickness of the right knee measured
using an InSize Digital Micrometer, Model 3109. Rats
from the DICL group received 7.5 mg (correspond-
ing to 30 mg/kg) of sodium diclofenac via a gastric
tube inserted orally once daily for 11 days.12,13 Rats
from the EUDPCL-T group were implanted with de-
vices containing 3.0 mgof sodium diclofenac(the
highest possible concentration being incorporated
into the matrix of EUD/PCL -T) in the popliteal re-
gion, medially to the biceps femoris tendon and lat-
erally to the semitendinosus muscle along the pos-
terior joint capsule of the right knee. Rats from the
CRGN and CONTROL groups did not receive any anti-
inflammatory drug.
The animals were anesthetized for the surgi-
cal procedures with an intraperitoneal injection of
ketamine hydrochloride (40mg/Kg of body weight)
combined with Xylazine (16 mg/Kg of body
weight).14
On the 4th day after initiation of treatment,
the rats were anesthetized again. Arthritis was in-
duced in the right knee of rats from the DICL,
EUDPCL-T and CRGN groups by intra-articular in-
jection (0.4 mL carrageenan (Sigma chemical CO,
USA), 3% saline). The right knee joint of rats in the
control group was injected 0.4 ml saline intra-
articularly.
Six hours after arthritis induction, 7 randomly
chosen rats in each group were anesthetized for knee
swelling measurement, followed by euthanasia for
resection of the right knee. The soft tissues of the
knee were collected for myeloperoxidase (MPO) and
nitrite/nitrate (NO) assay. Seven days after arthri-
tis induction, the remaining 7 rats in each group
underwent the same procedure. The diameter of
the knee joint was defined as the distance between
the regions of the medial and lateral collateral liga-
ment measured with a digital micrometer with the
knee in extension. The variation in the knee diam-
eter after carrageenan administration was deter-
mined based on the initial measured diameter.15
MPO and NO assay in the joint capsules
The joint capsules and periarticular tendon
structures of the sacrificed rats were removed and
homogenized in 0.3 mL saline, pH 7.4 with Turrax
homogenizer for 10 seconds. The homogenate was
placed in a freezer at -20°C for later analysis.16
 On the day of the experiment, the samples
were removed from the freezer and heated for 2 h
at 60°C in an oven for inactivation of endogenous
catalase activity. After heating, they were centri-
fuged at 12,000 g for 2 min. This centrifuged mate-
rial was used for the assessment of MPO activity
and nitrite concentrations.17
For the assessment of the MPO activity, 10 ìL
of the supernatant was pipetted and added to 200 ìL
of a buffer solution of potassium phosphate (pH=6)
containing 0.164 mg/mL of o-dianisidinedihydrochlo-
ride and 0.0005% hydrogen peroxide (H2O2).18H2O2
was broken down by MPO released from tissue
homogenates with0.5% hexadecyltrimethylammo-
nium bromide detergent. The resulting oxygen radi-
cal combined with the o-dianisidine was converted
into a colored compound. The formation of this com-
pound over time was measured using a Hitachi 2000
spectrophotometer at 650 nm at 37ºC. Data were
expressed as mU per mg of protein.19
Nitric oxide (NO) was quantified by detecting
its stable metabolites, nitrate (NO3) and nitrite
(NO2). The samples were deproteinized by adding
250 uL ofzinc sulfate (10%) and 350 ìL of sodium
hydroxide (2.5 N). Then, 300 ìL from washed of the
knee soft tissues were diluted in a 30 ìLsolution of
ammonium formate (150mM) and 30 ìLsodium phos-
phate (50mM). The solution was incubated for 2h
at 37°C, and then centrifuged (15000g, for 5 min).
About 250 ìL of the supernatant was collected in a
cuvette, and the same volume of Griess solution
(sulfanilamide (1%) (w:v), phosphoric acid (5%)
(v/v) and N-(1-naphthyl) ethylenediamine (0.1%)
(w:v) was added and incubated for 10 minutes at
room temperature. NO2 reaction produced a pink-
ish tinge, which was quantified by measuring ab-
sorbance using a Hitachi 2000 spectrophotometer
with a wavelength of 540 nm. Quantification of NO3
and NO2 expressed in ìM was determined by refer-
ence to a standard curve with previously known
concentrations (0-150 ìM).20
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Statistical anlaysis
The quantitative evaluation of knee swelling
in the rats, and MPO and nitrite/nitrate levels were
compared using analysis of variance (ANOVA), fol-
lowed by Tukey’s test for comparison of means, with
a 95% confidence level.
Results and discussion
Eudragit/PCL-T 900 blend is transparent when
pure (Figure 1). This feature can be altered by the
presence of sodium diclofenacin the matrix. Two
possible behaviors are expected from the addition
of sodium diclofenac in the matrix: (a) crystalliza-
tion of the drug during the production process, which
would produce opaque films; or (b) solubilization of
the drug in the polymeric matrix yielding transpar-
ent films.
It can be stated that the opacity of the ma-
trix indicates the non-solubilization of sodium
diclofenac in the polymer mixture and possible crys-
tallization of the drug in the EUDPCL-T matrix.
Mechanical properties
The application of polymeric blends in phar-
maceutical systems is dependent on their mechani-
cal properties. For example, for transdermal thera-
peutic systems, highly elastomeric polymeric films
are necessary to provide good skin coverage and
adhesion. Furthermore, in the case of implantable
Figure 2 - Stress-strain curves obtained from DMA analysis at 37oC
form EUD/PCL-T/Diclofenac(%) and EUD/PCL-T (%) devices measuring 11 mm x 1 mm.
Figure 1: Photos from EUD/PCL-T (A) and EUD/PCL-T/Diclofenac
implantable matrix.
devices, the ability to adapt to the implant site is
essential.21Pure polymer films of EUDRAGIT RS 100
exhibit a plastic mechanical behavior, which is at-
tributed to their semi-crystalline property. Although
they are good candidates for the production of films,
they are quite hard and require plasticizers to im-
prove their mechanical properties.22
Figure 2 shows the stress-strain curves ob-
tained from DMA analysis at 37oC form EUDPCL-T
and EUD/PCL-T/Diclofenac devices measuring 11
mm x 1 mm.
The result shows that the EUD/PCL-T/Di-
clofenac device has a progressive elongation varia-
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tion with increasing maximum tensile strength. This
behavior is different from that described in the lit-
erature for pure Eudragit RS films, a semi-crystal-
line polymer. Pure Eudragit RS films show a maxi-
mum tensile elongation of 6% and have a maxi-
mum tensile strength of 0.150 MPa.23The EUD/PCL-
T device showed a maximum tensile strength of
0.156 MPa, elasticity modulus of 0.86 MPa, and av-
erage capacity deformation up to 75% compared
with the initial size of the specimen. No statistical
difference (p<0.05) was observed between EUD/
PCL-T/Diclofenac and EUD/PCL-T, showing that the
Diclofenac content in the polymeric matrix did not
change the mechanical properties.
Studies show that the PCL-T can provide a plas-
ticizing effect on polymer materials.24This behavior
is associated with reduced molar weight and the large
number of hydroxyl groups in its chemical structure
favoring the intercalation within the polymer chains,
and the formation of chemical bonds between them.
The chemical structure of Eudragit RS shows a large
number of carbonyls available to make hydrogen
bonds with the hydroxyl groups of PCL-T, which ex-
plains the plasticizing effect.25The deformation ca-
pacity of this material is essential for producing a
device that will be implanted in the lateral region of
the knee, a site of constant muscle movement.
Drug release
Figure 3 shows the release profile of sodium
diclofenac from the EUDPCL-T films over a 25-day
period.
Drug delivery occurred in two phases. First,
an accelerated phase that lasted about 48 hours
with a mean release of 13%, which was associated
with the dissolution and release of diclofenac avail-
able on the matrix surface. Second, a phase that
showed a linear release behavior trend (r =.99148),
with a constant release of 0.022%/h.
That diltiazem hydrochloride release of poly-
ethylene-co-methyl acrylate matrices containing
PCL-T increase when the study was performed at a
temperature of 37oC.26This was explained by the
ability of PCL-T fusion at this temperature, a fact
that favors the simultaneous diffusion of the drug
and the PCL-T matrix. If the release of sodium
diclofenac from the matrix was solely dependent on
diffusion through the polymer matrix, the release
would probably follow a Fickian behavior, which
would cause a reduction in the amount of drug re-
leased due to time constraints. However, given that
the assay with EUDPCL-T device was conducted at
body temperature (37 ± 1.5oC), the PCL-T melting
and diffusion phenomena from the Eudragit matrix
associated with the dissolution and diffusion of
diclofenac favored the diclofenac release and pro-
vided a release mechanism after 48 hours following
zero-order kinetics, then promoting the controlled
drug release.
Anti-inflammatory activity of implanted device
Carrageenan-induced inflammation is acute,
non-immune and biphasic. In the initial phase (0-1
h) the release of histamine, serotonin and bradyki-
nin occurs. The subsequent phase (1-6 h) is corre-
lated with increased production of prostaglandins,
activation of COX-2 and nitric oxide release.27 Car-
rageenan-induced arthritis is dose dependent and
can produce a long-lasting effect in animal models.
Intra-articular injection of 3 mg carrageenan reduces
the latency of the mechanical withdrawal thresh-
old, so as to heat significantly in 4 hours, and lasts
for 7 weeks, whereas the effect of 1 mg dose lasts
for 3 weeks and a dose of 0.3 mg lasts for 24 h.28
The induced arthritis produces edema in the affected
joint that can be measured by the joint diameter
before and after the injection. In this model, the
diameter of the joint injected with carrageenan
reaches the maximum level within 8 hours after in-
jection, and gradually decreases depending on the
injected dose.15,28
Figure 3: Release profile of sodium diclofenacfrom the EUDPCL-T
devices at 37oC
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Figure 5: Variation in the carrageenan-induced knee edema in the
DICL group of Wistar rats treated for 11 days with sodium diclofenac
(30 mg/kg/day),  EUDPCL-T group (implant containing 3.0 mg),
CRGN and control groups 7 days after arthritis induction. (N =6, **
‘“ significant in relation to the CRGN group at p <0.05).
Figure 4: Variation in the carrageenan-induced knee edema in the
DICL group ofWistar rats treated for 4 days with sodium diclofenac
(30 mg/kg/day),  EUDPCL-T group (implant containing 3.0 mg),
CRGN and control groups 6 hours after arthritis induction. (N = 6,
** ‘“ significant in relation to the CRGN group at p <0.05)
Figure 4 shows the edema variation within 6
hours after carrageenan-induced arthritis in animals
previously treated for 4 days with sodium diclofenac
both orally and by the implanted devices.
When measurements of the knee circumfer-
ence were taken on day 7 after induction of arthri-
tis, all treated groups showed statistically signifi-
cant reduction in the edema compared with the
group that received only carrageenan. This arthri-
tis-induced model reaches an edema peak within 8
hours after injection, and gradually decreases. The
statistically significant response to treatment with
oral sodium diclofenac can be explained by the con-
tinuous administration of the drug.28
Based on these results, we may state that
the anti-inflammatory effect of EUDPCL-T device may
have been favored by the controlled release of the
drug to the joint, favoring the diffusion to the joint
capsule, and thence to the membrane and synovial
fluid, where there is known affinity with sodium
diclofenac and where the site of the drug action is
located.29
Figure 4 shows that DICL groups tended to
have edema reduction when compared with CRGN
groups, but no statistically significant difference was
found (p <0.05). The EUDPCL-T group showed a
statistically significant edema reduction compared
with the CRGN group. The dose of sodium diclofenac
administered orally was not enough to reduce sig-
nificantly the edema at a stage in which arthritis
induced by a high dose of carrageenan was very
close to its peak.
Figure 5 shows the variation in the edema
after 7 days of the induction of arthritis observed in
animals treated for 11 days with sodium diclofenac
orally and via the implanted device.
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Table I shows the mean and standard devia-
tion of the variation in MPO activity and nitrate/ni-
trite levels observed in animals at 6-hour and 7-
day intervals after arthritis induction.
Six hours after arthritis induction, oral ad-
ministration of diclofenac did not cause a signifi-
cant reduction in MPO levels; however, a statisti-
cally significant reduction was observed in the
EUDPCL-T group when compared with the CRGN
group (p<0.05). Seven days after arthritis induc-
tion, both the DICL and EUDPCL-T groups showed
statistically significant edema reduction compared
with the CRGN group in decreased MPO activity.
These results confirm what was observed in the
evaluation of knee edema, indicating a higher ac-
tivity of EUDPCL-T device when compared with oral
administration of diclofenac.
Six hours after carrageenan-induced arthri-
tis, the search for nitrates and nitrites in the DICL
group showed no statistical difference when com-
pared with the CRGN group. The EUDPCL-T group
had a reduction in nitrate/nitrite levels, a statisti-
cally significant difference when compared with the
CRGN group (p<0.05). On the seventh day after
the arthritis induction, which is a late phase of the
inflammatory process when these metabolites are
already at low levels, there was no difference in the
concentration of nitrates and nitrites between the
groups. This was an expected behavior because the
nitric oxide is identified as a mediator and regula-
tor of inflammatory responses associated with va-
sodilation that occurs in the early stages of the in-
flammatory process.20
Conclusion
The polymeric device made of Eudragit RS,
PCL-T and sodium diclofenac showed similar me-
chanical properties to elastomeric polymer products,
which is associated with the plasticizing effect of
PCL-T. The mechanism of sodium diclofenac release
from the Eudragit and PLC-T matrix showed two
release stages, the first rapid and the second with a
zero-order kinetic behavior. The proposed implant-
able device was able to produce anti-inflammatory
activity in the carrageenan-induced arthritis similar
to that obtained with oral treatment, but with lower
doses of the drug.
Table 1: Variation in MPO activity and nitrate/nitrite levels at 6-hour and 7 day after arthritis induction
MPO (mg/g protein) ± sd
Group Control CRGN DICL EUDPCL-T
6 hours 0.0079 ± 0.0011a 0.0240 ± 0.0078b 0.0183 ± 0.0022b,c 0.0153 ± 0.0029c
7 days 0.0079 ± 0.0011a 0.0209 ± 0.0041b 0.0137 ± 0.0012c,d 0.0109 ± 0.0013a,d
Nitrates / Nitrites (units) ± sd
Control Carrageenan Diclofenac EUDPCL-T
6 hours 0.0177 ± 0.0020a 0.0289 ± 0.0043b 0.0245 ± 0.0020b,c 0.0221 ± 0.0013c
7 days 0.0201 ± 0.0026a,b,d 0.0277 ± 0.0049d,b 0.0313 ± 0.0071d,b,c 0.0252 ± 0.0026d,c
Same letters meaning no statistical differences p<0.05
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